MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression

Molecular and Cellular Biochemistry

Volumn 396, Issue 1-2, 2014, Pages 295-305

  Li, Ruixin ^a   Yuan, Weijie ^a   Mei, Wenjuan ^a   Yang, Keda ^a   Chen, Zihua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

EphA2; Gastric cancer; Invasion; miR 520d 3p; Proliferation

Indexed keywords

3' UNTRANSLATED REGION; CCND1 PROTEIN, HUMAN; CYCLIN D1; EPHRIN RECEPTOR A2; GELATINASE B; MICRORNA; MIRN520 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; AGED; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; ONCOGENE MYC; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

3' UNTRANSLATED REGIONS; AGED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICRORNAS; MIDDLE AGED; RECEPTOR, EPHA2; STOMACH NEOPLASMS;

EID: 84907592730     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2164-6     Document Type: Article

References (37)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed 11 June 2014
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917. doi: 10.1002/ijc.25516
3. Terry MB, Gaudet MM, Gammon MD (2002) The epidemiology of gastric cancer. Semin Radiat Oncol 12:111-127
4. Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143-159. doi: 10.1002/emmm.201100209
5. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
6. Song JH, Meltzer SJ (2012) MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 143:35-47. doi: 10.1053/j.gastro.2012.05.003
7. Song S, Ajani JA (2013) The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol 10:109-118. doi: 10.1038/nrgastro.2012.210
8. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J, Sung JJ (2010) MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29:5761-5771. doi: 10.1038/onc.2010.352
9. Song F, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X, Chen K (2014) Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res 20:878-889. doi: 10.1158/1078-0432.CCR-13-1844
10. Kogo R, Mimori K, Tanaka F, Komune S, Mori M (2011) Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 17:4277-4284. doi: 10.1158/1078-0432.CCR-10-2866
11. Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC, Lee JH, Lee SS, Ashktorab H, Smoot DT, Ryu KW, Kim YW, Choi IJ (2014) MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. PLoS ONE 9:e85205. doi: 10.1371/journal.pone.0085205
12. Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, Hou F, Ge J, Zhong M, Tang Y, Xia X, Chen Z (2014) EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells. Oncogene 33:2737-2747. doi: 10.1038/onc.2013.238
13. Hou F, Yuan W, Huang J, Qian L, Chen Z, Ge J, Wu S, Chen J, Wang J, Chen Z (2012) Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol 29:2691-2700. doi: 10.1007/s12032-011-0127-2
14. Yuan WJ, Ge J, Chen ZK, Wu SB, Shen H, Yang P, Hu B, Zhang GW, Chen ZH (2009) Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 54:2410-2417. doi: 10.1007/s10620-008-0649-4
15. Yuan W, Chen Z, Wu S, Ge J, Chang S, Wang X, Chen J, Chen Z (2009) Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res 15:473-478. doi: 10.1007/s12253-008-9132-y
16. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, De Filippis L, Mangiola A, Maira G, Anile C, De Bonis P, Reynolds BA, Pasquale EB, Vescovi AL (2012) The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22:765-780. doi: 10.1016/j.ccr.2012.11.005
17. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M et al (2013) Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 3:1302-1315. doi: 10.1158/2159-8290.CD-13-0159
18. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK (2008) EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7:1098-1103
19. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145-5150
20. Cui XD, Lee MJ, Kim JH, Hao PP, Liu L, Yu GR, Kim DG (2013) Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. Hepatology 57:2248-2260. doi: 10.1002/hep.26253
21. Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL, Date H (2012) Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer 76:431-438. doi: 10.1016/j.lungcan.2011.12.004
22. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15:4423-4430. doi: 10.1158/1078-0432.CCR-09-0473
23. Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen J (2011) Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS ONE 6:e24426. doi: 10.1371/journal.pone.0024426
24. Herath NI, Spanevello MD, Doecke JD, Smith FM, Pouponnot C, Boyd AW (2012) Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur J Cancer 48:753-762. doi: 10.1016/j.ejca.2011.07.003
25. Tawadros T, Brown MD, Hart CA, Clarke NW (2012) Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells. Br J Cancer 107:1737-1744. doi: 10.1038/bjc.2012.457
26. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H, Zhang X (2014) miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res 20:2617-2630. doi: 10.1158/1078-0432.CCR-13-3224
27. Aydoʇdu E, Katchy A, Tsouko E, Lin CY, Haldosén LA, Helguero L, Williams C (2012) MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 33:1502-1511. doi: 10.1093/carcin/bgs161
28. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, Cao S, Lin X (2011) Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS ONE 6:e16264. doi: 10.1371/journal.pone.0016264
29. Yuan W, Chen Z, Chen Z, Wu S, Guo J, Ge J, Yang P, Huang J (2012) Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma 59:105-113
30. Coburn NG (2009) Lymph nodes and gastric cancer. J Surg Oncol 99:199-206. doi: 10.1002/jso.21224
31. Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R (2010) EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 285:18575-18585. doi: 10.1074/jbc.M109.075085
32. Li X, Wang Y, Wang Y, Zhen H, Yang H, Fei Z, Zhang J, Liu W, Wang Y, Zhang X (2007) Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis. Tumour Biol 28:165-172
33. Tandon M, Vemula SV, Mittal SK (2011) Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15:31-51. doi: 10.1517/14728222.2011.538682
34. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512
35. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426
36. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18:2883-2891
37. Wu B, Crampton SP, Hughes CC (2007) Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 26:227-239